Placebo + Donanemab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Feb 2023: Trial registered, NCT05738486
  2. 28 Feb 2023: Trial started, NCT05738486

The trials

NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

State
Under way
Phase
Phase 3
People
1,175 taking part
Started
28 Feb 2023
Primary completion
16 May 2024
Arms
1400 mg Donanemab - Standard Regimen, 1400 mg Donanemab - Dose Skipping, 1400 mg Donanemab - Titration, 1400 mg Donanemab - Maximum Concentration (Cmax), Donanemab Addendum 2 Arm 1
Results
Posted on the registry
  1. 22 Feb 2023: Trial registered
  2. 28 Feb 2023: Trial started
  3. 14 Nov 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.